Fig. 6: M2T-CD33 treatment is safe and tolerable in mice.

A Mice were treated with 5 µg M2T-CD33 or PBS every other week for three doses. Plasma was taken 1 week after the third dose. Plasma from mice treated with anti-CD40 antibody was used as a positive control. Heatmap of plasma cytokine levels measured by cytometric bead array. B−D Mice were treated with the mouse version of M2T-CD33 at 0.1 nmol, 2 nmol, or 4 nmol every other week for a total of three doses and untreated mice were used as a control (N = 3). Error bars represent SEM. B Change in body weight throughout M2T-mCD33 treatment. C Complete blood count with differential from mice 1 week after third M2T-mCD33 dose. D Plasma chemistry analysis from mice 1 week after third M2T-mCD33 dose. E Mice were treated with 4 nmol of M2T-mCD33 or PBS every other week for a total of three doses. Quantification of flow cytometry showing frequencies of indicated populations in total live bone marrow cells 1 week after third M2T-mCD33 treatment (N = 6). Error bars represent SEM. Significance was determined by Mann-Whitney test, *P < 0.05, ns=not significant.